Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.56 |
| ▸ | SLC28A1 | O00337 | 2/20 | 0.52 |
| ▸ | PI4KA | P42356 | 3/20 | 0.52 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.52 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.52 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.49 |
| ▸ | GMPS | P49915 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.49 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.49 |
| ▸ | GAPDH | P04406 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | STAT6 | P42226 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28867974 | 0.87 | ADORA2A (0.55) | ADORA2ASLC28A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL17460353 | 0.87 | ADORA2A (0.42) | ADORA2ASLC28A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL28037447 | 0.86 | ADORA2A (0.54) | ADORA2ASLC28A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL29081873 | 0.86 | ADORA2A (0.54) | ADORA2ASLC28A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL30716566 | 0.85 | ADORA2A (0.53) | ADORA2ASLC28A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL12987542 | 0.85 | ADORA2A (0.51) | ADORA2ASLC28A1PI4KAPI4K2BPI4K2A | |
| SCHEMBL12987535 | 0.85 | ADORA2A (0.45) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL6829141 | 0.85 | ADORA2A (0.45) | ADORA2API4KAPI4K2BPI4K2API4KB | |
| SCHEMBL1300019 | 0.83 | TAS1R3 (0.56) | TAS1R3TAS1R1ADORA1SMN1; SMN2POLB | |
| SCHEMBL28294010 | 0.83 | ADORA2A (0.49) | ADORA2ASLC28A1PI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120064427-A | Method and analysis system for detecting brain nucleic acid hydrolysate spatial distribution based on mass spectrum imaging | 北京脑科学与类脑研究所 | 2025-05-30 | — | — | CN | claimed |
| EP-4384635-A1 | IN SITU EPITRANSCRIPTOMIC PROFILING | The Broad Institute Inc. (US) | 2024-06-19 | — | — | EP | claimed |
| WO-2024086659-A2 | COMPOSITION AND METHODS FOR DETECTING ADENINE MODIFICATIONS | THE UNIVERSITY OF CHICAGO (US) | 2024-04-25 | — | — | WO | claimed |
| CN-116298235-A | Serum metabolism biomarker for diagnosing or monitoring breast cancer and screening method thereof | 哈尔滨医科大学 | 2023-06-23 | — | — | CN | claimed |
| WO-2023023055-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-02-23 | — | — | WO | claimed |
| WO-2023018756-A1 | IN SITU EPITRANSCRIPTOMIC PROFILING | THE BROAD INSTITUTE, INC. (US) | 2023-02-16 | — | — | WO | claimed |
| CN-114076805-B | Method for enriching methylated adenosine in urine and application thereof | 浙江大学 | 2022-07-26 | — | — | CN | claimed |
| WO-2022115822-A2 | METHODS FOR FULL-LENGTH REVERSE TRANSCRIPTION PCR OF LONG RNAS CONTAINING MODIFIED RIBONUCLEOSIDES USING A THERMOSTABLE REVERSE TRANSCRIPTASE | NORTHWESTERN UNIVERSITY (US) | 2022-06-02 | — | — | WO | claimed |
| CN-114076805-A | Method for enriching methylated adenosine in urine and application thereof | 浙江大学 | 2022-02-22 | — | — | CN | claimed |
| CN-104804903-B | Semiconductor cleaning agent with metal line | 恩特格里斯公司 | 2018-10-30 | — | — | CN | claimed |
| CN-106399506-A | Diagnostic methods for determining prognosis of non-small cell lung cancer | 雅培分子公司 | 2017-02-15 | — | — | CN | claimed |
| EP-2755986-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | Moderna Therapeutics, Inc. (US) | 2014-07-23 | — | — | EP | claimed |
| WO-2013039857-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | modeRNA Therapeutics (US) | 2013-03-21 | — | — | WO | claimed |
| WO-2001085220-A1 | LABELED NUCLEOSIDES AND METHOD FOR THEIR PREPARATION | RNA-TEC N.V. (BE) | 2001-11-15 | — | — | WO | claimed |
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC (US) | 2026-05-28 | — | — | US | disclosed |
| US-12630527-B2 | Broad spectrum anti-cancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260078415-A1 | Differential Knockout of an Allele of a Heterozygous Elane Gene | EMENDOBIO INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-0708781-A1 | A 3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1996-05-01 | — | — | EP | disclosed |
| EP-0269574-A2 | Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1988-06-01 | — | — | EP | disclosed |
| EP-0238672-A1 | PROCESS FOR DEOXIDIZING ALCOHOL | Yamasa Shoyu Kabushiki Kaisha (JP) | 1987-09-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630527-B2 | Broad spectrum anti-cancer compounds | YTHDF3, YTHDF1, YTHDF2 | ADORA2A 2387/4885SLC28A1 1430/4885PI4KA 1587/4885 |
| US-20260146040-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CTRB1, CTRB2, CPN1 | ADORA2A 4503/4885SLC28A1 3074/4885PI4KA 3746/4885 |
| US-20260078415-A1 | Differential Knockout of an Allele of a Heterozygous Elane Gene | ELANE, ENDOD1, UPF1 | ADORA2A 4101/4885SLC28A1 1216/4885PI4KA 3355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.